FDA's AI guidance sparks confusion among biopharma companies

Tala Fakhouri, a former AI regulator now in industry, says biopharma firms are misinterpreting the FDA's AI guidance by being too cautious. She argues the FDA should offer clearer directives to help companies innovate without unnecessary fear of non-compliance. This highlights ongoing tension in how quickly cutting-edge tech can integrate into regulated health sectors.